Non-small cell lung cancer (NSCLC) with higher blood tumor mutational burden (bTMB)/tissueTMB (tTMB) ratio is associated with inferior survival outcome

被引：0
|
作者：
Kim, Leeseul
Park, Jewel
Oh, Youjin
Chae, Young Kwang
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3376
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3376
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy
    Hendriks, Lizza E.
    Rouleau, Etienne
    Besse, Benjamin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 647 - 660
  • [22] Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782
    Bar, Jair
    Esteban, Emilio
    Rodriguez-Abreu, Delvys
    Aix, Santiago Ponce
    Szalai, Zsuzsanna
    Felip, Enriqueta
    Gottfried, Maya
    Provencio, Mariano
    Robinson, Andrew
    Fulop, Andrea
    Rao, Suman Bannur
    Camidge, D. Ross
    Speranza, Giovanna
    Townson, Steven M.
    Kobie, Julie
    Ayers, Mark
    Dettman, E. J.
    Hunkapiller, Nathan
    Mcdaniel, Robert
    Jung, Byoungsok
    Burkhardt, David
    Mauntz, Ruth
    Csoszi, Tibor
    LUNG CANCER, 2024, 190
  • [23] Tumor regression as a continuous variable and survival in advanced non-small cell lung cancer (NSCLC).
    Stewart, David J.
    Lu, Charles
    Saintigny, Pierre
    Goss, Glenwood D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Mutational signatures in the perspective of tumour mutational burden in patients with non-small cell lung cancer
    Van den Heuvel, G.
    Kroeze, L.
    Ligtenberg, M.
    Grunberg, K.
    von Rhein, D.
    Jansen, E.
    de Voer, R.
    Van den Heuvel, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1217 - S1218
  • [25] Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
    Cai, Liangliang
    Bai, Hua
    Duan, Jianchun
    Wang, Zhijie
    Gao, Shugeng
    Wang, Di
    Wang, Shuhang
    Jiang, Jun
    Han, Jiefei
    Tian, Yanhua
    Zhang, Xue
    Ye, Hao
    Li, Minghui
    Huang, Bingding
    He, Jie
    Wang, Jie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [26] Does blood sugar impact on metastatic non-small cell lung cancer (NSCLC) outcome?
    Gravel, Mathieu
    Blais, Normand
    Tehfe, Mustapha Ali
    Florescu, Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival
    Wang, Zhaoxi
    Choi, Sojung
    Lee, Jinseon
    Huang, Yen-Tsung
    Chen, Feng
    Zhao, Yang
    Lin, Xihong
    Neuberg, Donna
    Kim, Jhingook
    Christiani, David C.
    CANCER INFORMATICS, 2015, 14 : 1 - 9
  • [28] FAM13A is associated with non-small cell lung cancer (NSCLC) progression and controls tumor cell proliferation and survival
    Eisenhut, Felix
    Heim, Lisanne
    Trump, Sonja
    Mittler, Susanne
    Sopel, Nina
    Andreev, Katerina
    Ferrazzi, Fulvia
    Ekici, Arif B.
    Rieker, Ralf
    Springel, Rebekka
    Assmann, Vera L.
    Lechmann, Matthias
    Koch, Sonja
    Engelhardt, Marina
    Warnecke, Christina
    Trufa, Denis I.
    Sirbu, Horia
    Hartmann, Arndt
    Finotto, Susetta
    ONCOIMMUNOLOGY, 2017, 6 (01):
  • [29] The landscape of intra-tumor heterogeneity (ITH) and its association with actionable mutation and blood tumor mutation burden (bTMB) in patients with non-small cell lung cancer (NSCLC) assessed by circulating tumor DNA (ctDNA)
    Kim, Leeseul
    Lee, Yeun Ho
    Kim, Hye Sung
    Choi, Horyun
    Kim, Jinah
    Chae, Young Kwang
    CANCER RESEARCH, 2022, 82 (12)
  • [30] Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma Preface
    Ilie, Marius
    Hofman, Paul
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 614 - 615
12345